Skinbiotherapeutics Share Discussion Threads

[albanyvillas] 16/10/2017 20:00

Next placing at 5p lads

[elrico] 16/10/2017 19:11

After very careful analysis of ALBANYVILLAS outstanding analytical contributions, I have reluctantly decided to save my blushes and follow Bob on this one.

ALBANYVILLAS 16 Oct '17 - 11:54 - 712 of 713 0 0 (Filtered)

[bobalot] 16/10/2017 16:49

AND YOU ARE A TOTAL IDIOT

ALBANYVILLAS 16 Oct '17 - 16:28 - 718 of 718    0   0 (Filtered)

A NASTY DERAMPER FOOL

[bobalot] 16/10/2017 12:34

Q4: So, what is next for Skinbiotherapeutics, what should investors be looking out for in terms of news flow?

A4: I think it’s a very exciting time, both for our company and also for the skin microbiome sector as a whole so just a couple of weeks ago, I was at a scientific conference, a Wellcome Trust-funded conference, looking at the microbiome and how it interreacts with humans so this whole area is vibrant.

Specifically, for Skinbiotherapeutics, on Thursday of this week we’ve got our maiden final year results being issued so we’ll maybe be speaking again! Also, we’re continuing now preparing for the initial human study and, as I said, moving forward the early-stage commercial discussions but it’s important to stress that these are early-days.

For the sector as a whole, as I’ve suggested, the area is gaining a very increasing level of interest and attention so I think exciting times ahead of us, yes.

[bobalot] 16/10/2017 12:33

Q3: This is the first announcement that you’ve made since IPO in April, there seems quite a bit of news here?

A3: Yes, what we wanted to do on the back of cytotoxicity results, which of course are a material set of data, we wanted to give the market a full update really of what we have been doing and when we give an update we want it to be robust and of material value so hopefully, that’s what we’ve achieved today.

[bobalot] 16/10/2017 12:33

Q2: Now, you also provided a scientific update to the market, what were the key points that investors should take from that?

A2: I think it’s more an operational update really, it’s not just a scientific update, we’ve actually been making progress across the board really.

So, in terms of the science, we’ve now shown that our SkinBiotix technology, we’ve shown the doses at which it needs to be applied for all three of our programmes, which if you remember are a cosmetic programme, an infection programme and an eczema programme, so we’ve defined doses for those. We’ve also done a timed course in respect of the infection programme so we know how often we’d have to treat the skin now for full effect.

Other areas where we’ve made a lot of progress are the manufacture scale up so, of course, we need scale up because we need to be able to make our product in larger amounts so we’ve made some headway with that. We’ve also started formulation work so making progress right across the board really and there are even some early commercial discussions underway too.

[bobalot] 16/10/2017 12:32

Skinbiotherapeutics PLC Q&A: Passing Cytotoxicity Tests & Scientific Update (LON:SBTX)
Posted by: Amilia Stone 6th October 2017

Skinbiotherapeutics PLC (LON:SBTX) Chief Executive Officer Dr. Catherine O’Neill caught up with DirectorsTalk for an exclusive interview to discuss passing third party cytotoxicity tests, their scientific update to the market & what’s next for the company

[2350220] 16/10/2017 11:51

Here's a link to an interesting article in the Sunday Times, about microbiome in skincare products I put on the Opti board :


John

[bobalot] 13/10/2017 14:23

Last Tuesday Dr. Cath gave a presentation about: The use of probiotics to modify the gut-skin axis in health and disease Dr. Catherine O’Neill, Centre for Dermatology Research, The University of Manchester, UK

Quite an interesting conference where it also had an industry exhibition hall:



CREATING MORE AWARENESS ABOUT SKINBIO.

[elrico] 12/10/2017 14:23

ODR - IMHO SBTX sentiment will change for the good ahead of its own news as and when OPTI sentiment changes. It has followed the OPTI trading cycle thus far, I don't see it changing in the SHORT TERM. Accumulate mode :)

AIM hasn't changed as far as I'm aware....well, not for the good. There are countless examples of AIM companies run up by pump and self promoting CEO's. HNR, FFWD, TERN, and a whole raft of oilies pumped up ahead of the drill bit - SOU springs to mind. Our's at SBTX and OPTI are building companies on solid science and creeping commercial process.

[bobalot] 12/10/2017 14:07

At least the share price bounces off the lower support floor.

[onedayrodders] 12/10/2017 13:50

I don't think it's a question of hearing .. just like OPTI, today's AIM only wants to see hard cash, no longer do SP's run up on excitement and potential alone, even important milestones are ignored.

Unless we get some news from left field here, our best short term chances are to ride the coat tails of revenue news from OPTI which should mean sentiment and confidence here will improve and share price advances will find a higher support level.

[bobalot] 12/10/2017 13:23

No problem, there is a long pipeline of news flow in the coming weeks and months, even the tone deaf will get the message --- lol.

[onedayrodders] 12/10/2017 12:44

it appears no one's listening bobalot

[bobalot] 11/10/2017 14:25

Here's a recap on last weeks announcement --- it shows the business has a lot of potential.

Scientific update

As outlined at IPO in April 2017, SkinBioTherapeutics has been concentrating on further developing its technology towards the three applications in skin care, anti-infection and skin repair.

The positive cytotoxicity result above is a key milestone. However, other work is progressing well and the Company has summarised this below:

-     Manufacture: work on scale-up has been initiated, confirmed by the successful manufacture of SkinBiotix® ;by an external partner

-     Pilot scale formulation has been initiated by an external partner with expertise in cosmetic formulation development. Phase one of three is complete; testing of solubility and preservative requirements of the technology. Phase two, identifying a final blend for testing, is currently underway

-     Early stage commercial discussions are ongoing with both potential manufacturing partners as well as potential licensees

-      Anti-infection and eczema programmes

o  A 'time-course' study, has confirmed that the frequency of application required for protection is three times daily. Therefore, protection against Staphylococcus aureus infection for both eczema and infection programmes requires application every five hours*

-      Regulatory process has commenced and a regulatory consultant has been appointed 

-      Ongoing scientific studies:

o Defining dosage is complete - for all three applications. SkinBioTherapeutics has finalised a dosing level at which the technology will be used which maintains the viability of the skin cells

o  Confirmation of the modifying property of SkinBiotix® ;on protein composition of the skin, increasing the expression of Claudin 4, an essential component in tight junctions which are critical for the barrier characteristic of skin

*These data were recently presented at a Wellcome Trust conference: "Host Microbiome Interactions in Health and Disease".

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:
"This announcement demonstrates the excellent progress SkinBioTherapeutics is making at all levels - scientific, development, manufacture and commercial.

"The result from the cytotoxicity testing by Charles River is essential external validation of our SkinBiotix® ;platform.  This was one of the key milestones to pass and was highlighted as such at the IPO. Its passing marks a critical step in our progression and the transitioning of the technology into human validation studies.

"Operationally, we are on track. The development programmes are progressing well, we are generating further scientific data on SkinBiotix® ;confirming its suitability for application to skin, and industry awareness of our technology is growing."

[slartybartfaster] 11/10/2017 14:11

Based on what?
These tops ups are great if you have the funds, freaking painfully annoying when not. Sick to death of this range bound bs and wanna be traders.

[onedayrodders] 11/10/2017 13:07

yet ANOTHER top up opportunity .. never ending

[bobalot] 11/10/2017 11:45

By that time the share price might be in the 50p - 60p range as a guesstimate.

[pglancy] 10/10/2017 16:22

De risked after the human trials and a commercial agreement in place.

[elrico] 10/10/2017 11:43

Vanduke - I enjoy the researching aspect of both companies, especially OPTI because there are so many facets to it. There's no emotion attachment, period.

Myself and Bob were having a cordial exchange of views. If you have problem with this, then use the filter option.

I would have thought you would have learned from your last advisory to me.

I'll leave you to your emotional attachment to your so called syndicate and inform us mere mortals your accumulating.

No offence, but I'm filtering you because it is best for this BB.

[bobalot] 10/10/2017 09:18

The prospects for SkinBio have improved considerably, since the health and safety approval it has been effectively derisked after passing that key milestone.

[vanduke] 10/10/2017 08:13

Elrico, no offence intended please. Your last post and posts here are an example of your emotional attachment to OPTI and now SBTX. Step back for a while or you will loose all objectivity.